Abstract:Autophagy inhibition could hinder the underlying protective mechanisms in the course of tumor treatment. The advances in autophagy inhibition have driven focus on the functionalized nanoplatforms by combining the current treatment paradigms with complementary autophagy inhibition for enhanced efficacy. Furthermore, Ca2+ overload is also a promising adjuvant target for the tumor treatment by augmenting mitochondrial damage. In this view, complementary mitochondrial Ca2+ overload and autophagy inhibition were first demonstrated as a novel strategy suitable for homing in on the shortage of photodynamic therapy (PDT). We constructed biodegradable tumor-targeted inorganic/organic hybrid nanocomposites (DPGC/OI) synchronously encapsulating IR780 and Obatoclax by biomineralization of the nanofilm method, which consists of pH-triggered calcium phosphate (CP), long circulation phospholipid block copolymers 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE)-poly(ethylene glycol) (PEG)2000-glucose (DPG). In the presence of the hydrophilic PEG chain and glucose transporter 1 (Glut-1) ligands, DPGC would become an effectively tumor-oriented nanoplatform. Subsequently, IR780 as an outstanding photosensitizer could produce increased amounts of toxic reactive oxygen species (ROS) after laser irradiation. Calcium phosphate (CP) as the Ca2+ nanogenerator could generate Ca2+ at low pH to induce mitochondrial Ca2+ overload. The dysfunction of mitochondria could enhance increased amounts of ROS. Based on the premise that autophagy would degrade dysfunctional organelles to sustain metabolism and homeostasis, which might participate in resistance to PDT, Obatoclax as an autophagy inhibitor would hinder the protective mechanism from cancer cells with negligible toxicity. Such an enhanced PDT via mitochondrial Ca2+ overload and autophagy inhibition could be realized by DPGC/OI.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsami.1c11583.Scanning electron microscope (SEM) imaging of CP, DPGC, and DPGC/OI (Figure S1); size distribution of DPGC/OI in serum (Figure S2); FT-IR of CP, DPGC, and DSPE-PEG-glucose (Figure S3); TEM images of DPGC/OI after incubation for 0.5 h in (Figure S4A) pH 5.2 and (Figure S4B) pH 7.4, respectively; temperature curves of IR780 + NIR and DPGC/OI + NIR after 1 min laser irradiation (Figure S5); release profiles of IR780 and Obatoclax from DPGC/OI (Figure S6A,B); CLSM images of 4T1 cancer cells treated with DPGC/I at different time points (Figure S7); ROS generation in 4T1 cells after treatment with IR780 and CP/I upon laser exposure after 48 h (Figure S8); matching histogram analysis of cleaved Caspase-3 (Figure S9); live and dead images of 4T1 cells treated with different treatments for 48 h (Figure S10); histogram Individual blood analysis of mice at 15 days after different treatments (Figure S11); tumors dissected from mice after 15 days with H&E and TUNEL staining (Figure S12); H&E staining of tissues collected from mice after 15 days of different treatments, scale bar = 200 μm (Figure S13); relative volume changes (Figure S14A) and mice body weight changes in different groups (Figure S14B), data are mean ± SD, n = 5; *P < 0.05, **P < 0.01, and ***P < 0.001 vs control; photographs of tumors ex vivo in different treatment groups within 15 days (Figure S14C) (PDF)This article has not yet been cited by other publications.

3-Bromopyruvate-conjugated Nanoplatform-Induced Pro-Death Autophagy for Enhanced Photodynamic Therapy Against Hypoxic Tumor

Oxygen-economizing Liposomes for Synergistic Photodynamic and Starvation Therapy

Mitochondria-targeted nanoplatforms for enhanced photodynamic therapy against hypoxia tumor

Engineering mitochondrial uncoupler synergistic photodynamic nanoplatform to harness immunostimulatory pro-death autophagy/mitophagy

A pro-death autophagy-based nanoplatform for enhancing antitumour efficacy with improved immune responses

An intelligent ZIF-8-gated polydopamine nanoplatform for in vivo cooperatively enhanced combination phototherapy

"Transforming enemy into friend" strategy-based stimuli responsive dual-drug liposomes for synergistic chemo-photodynamic therapy

Oxygen-producing catalase-based prodrug nanoparticles overcoming resistance in hypoxia-mediated chemo-photodynamic therapy

Tumor microenvironment-responsive intelligent nanoplatform with oxygen self-supply for synergistic chemotherapy/photodynamic therapy/photothermal therapy against hypoxic tumors

A "Chase and Block" Strategy for Enhanced Cancer Therapy with Hypoxia‐Promoted Photodynamic Therapy and Autophagy Inhibition Based on Upconversion Nanocomposites

ROS-responsive self-assembly nanoplatform overcomes hypoxia for enhanced photodynamic therapy

NIR-Light-Intensified Hypoxic Microenvironment for Cascaded Supra-Prodrug Activation and Synergistic Chemo/Photodynamic Cancer Therapy

Tumor acidity/redox hierarchical-activable nanoparticles for precise combination of X-ray-induced photodynamic therapy and hypoxia-activated chemotherapy.

Photodynamic Therapy-Accelerated Hypoxia-Responsive Prodrug Release for Synergistic Photo-Chemotherapy of Melanoma Cancer based on Noncovalent Interactions

Supramolecular Nanoplatform for Imaging-Guided Phototherapies via Hypoxia Tumour Microenvironment Remodeling

ROS-sensitive biomimetic nanocarriers modulate tumor hypoxia for synergistic photodynamic chemotherapy

Programmable therapeutic nanoscale covalent organic framework for photodynamic therapy and hypoxia-activated cascade chemotherapy

Colloidally Stabilized DSPE-PEG-Glucose/Calcium Phosphate Hybrid Nanocomposites for Enhanced Photodynamic Cancer Therapy via Complementary Mitochondrial Ca 2+ Overload and Autophagy Inhibition

A Redox-Triggered Autophagy-Induced Nanoplatform with PD-L1 Inhibition for Enhancing Combined Chemo-Immunotherapy

ROS Responsive Nanoparticles Encapsulated with Natural Medicine Remodel Autophagy Homeostasis in Breast Cancer

Application of tumor pH/hypoxia-responsive nanoparticles for combined photodynamic therapy and hypoxia-activated chemotherapy